Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources

Allogeneic hematopoietic cell transplantation (HCT) is a curative therapeutic modality for most malignant and non-malignant hematological disorders. However, this treatment could be associated with a substantial risk of subsequent non-relapse mortality (NRM). Pre-transplant comorbidities, as evaluated by the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), have been shown to provide accurate estimates about post allogeneic HCT NRM [1]. The prognostic value of the HCT-CI was further augmented by the addition of a score of 1 for ages ≥40 years [2] and scores for values of serum levels of ferritin, albumin, and platelet count [3] (this index herein designated “augmented comorbidity/age”).

Source: Biology of Blood and Marrow Transplantation - November 27, 2018 Category: Hematology Authors: Mahmoud Elsawy, Barry E. Storer, Filippo Milano, Brenda M. Sandmaier, Colleen Delaney, Rachel B. Salit, Ahmed H. Rashad, Ann E. Woolfrey, Frederick R. Appelbaum, Rainer Storb, Mohamed L. Sorror Source Type: research